Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by PRICE, C. J.
Right arrow Articles by MARR, M. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by PRICE, C. J.
Right arrow Articles by MARR, M. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1987 Oxford University Press

research-article

The Developmental Toxicity of Diethylene Glycol Dimethyl Ether in Mice1

CATHERINE J. PRICE*,2, CAROLE A. KIMMEL{dagger}, JULIA D. GEORGE* and MELISSA C. MARR*

*Chemistry and Life Sciences, Center for Life Sciences and Toxicology, Research Triangle Institute P.O. Box 12194, Research Triangle Park, North Carolina 27709-2194 {dagger}Nalional Toxicology Program/Reproductive Effects Assessment Group RD 689, U.S. Environmental Protection Agency, 401 M Street, S. W., Washington, D.C. 20460

The Developmental Toxicity of Diethylene Glycol Dimethyl Ether in Mice. PRICE, C. J., KIMMEL, C. A., GEORGE, J. D., AND MARR, M. C. (1987). Fundam. Appl. Toxicol. 8, 115–126. Diethylene glycol dimethyl ether (diEGdiME) is structurally related to several compounds which produce reproductive and developmental toxicity, including teratogenicity in laboratory animals. In the present study, diEGdiME (0, 62.5, 125, 250, or 500 mg/kg/day) was administered by gavage in distilled water to timed-pregnant CD-1 mice during major organogenesis [gestational days (gd) 6–15]. Clinical status of treated females was monitored daily during treatment and on gd 17. At sacrifice (gd 17), pregnancy was confirmed by uterine examination for 20–24 dams per group; each live fetus was examined for external, visceral, and skeletal malformations. No maternal deaths, morbidity, or treatment-related clinical signs were observed. Reduced maternal weight gain during treatment at ≥250 mg/kg/day was primarily attributed to compromised pregnancy status resulting in reduced gravid uterine weight. Maternal weight gain during gestation corrected for gravid uterine weight, and relative liver weight (% body weight) were not affected. Average fetal body weight/litter was significantly reduced at ≥ 125 mg/kg/day. The percentage of postimplantation loss/litter (5, 8, 7, 12, and 50% for control through high dose) and the percentage of malformed live fetuses/litter (0.4, 0, 2, 24, and 96%) were significantly increased at ≥ 250 mg/kg/day. Developmental defects involved primarily the neural tube, limbs and digits, craniofacial structures, abdominal wall, cardiovascular system, urogenital organs, and both the axial and appendicular skeleton. In summary, oral administration of diEGdiME during major organogenesis did not produce any distinctive signs of maternal toxicity, but did produce selective and profound adverse effects upon fetal growth, viability, and morphological development at ≥ 125 mg/kg/day.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.